NCT Research

Contact

 

Prof. Dr. Kari Hemminki
Phone: +49 6221 421800

E-mail: k.hemminki@dkfz.de

 

 

Labor omnia...

 

vincit.

Molecular Genetic Epidemiology

DKFZ
 
 
 

Our group/department has:

  • Demonstrated that familial risk of cancer does not only affect young cancer patients (Kharazmi et al. BMJ 2012)

  • Showed that TERT promoter muations are the most common feature of sporadic melanoma (Horn et al. Science 2013)

  • Showed for the first time that translocations may have a genetic basis (Weinhold et al. Nature Genet 2013).

  • Provided evidence that a common course for non-Hodgkin lymphoma in eldely patients is senile systemic amyloidosis (Hemminki et al. Annals Oncol 2014).

  • Added 4 new genetic susceptibility loci to our previously detected 3 loci in multiple myeloma (Chubb et al. Nature Genet 2013).

2010 – 2013

  • Kharazmi, E., M. Fallah, K. Sundquist and K. Hemminki. Familial risk of early and late onset cancer: nationwide prospective cohort study. BMJ 2012;345: e8076.

  • Horn, S., A. Figl, P. S. Rachakonda, C. Fischer, A. Sucker, A. Gast, S. Kadel, I. Moll, E. Nagore, K. Hemminki, D. Schadendorf and R. Kumar. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959-61.

  • Weinhold, N., D. C. Johnson, D. Chubb, B. Chen, A. Försti, F. J. Hosking, P. Broderick, Y. Ma, S. E. Dobbins, D. Hose, B. A. Walker, F. E. Davies, M. F. Kaiser, N. L. Li, W. A. Gregory, G. H. Jackson, M. Witzens-Harig, K. Neben, P. Hoffmann, M. M. Nöthen, T. W. Mühleisen, L. Eisele, F. M. Ross, A. Jauch, H. Goldschmidt*, R. S. Houlston*, G. J. Morgan* and K. Hemminki*. The CCND1 G870A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.  Nature Genet. 2013;45:522-5.

  • Hemminki K, Li X, Forsti A, Sundquist J, Sundquist K. Non-Hodgkin lymphoma in familial amyloid polyneuropathy patients in Sweden. Blood, 2013; 122:458-9.

  • Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JA, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dörner E, Allan JM, Jauch A, Morgan GJ*, Hemminki K*, Houlston RS*, Goldschmidt H*. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. 2013 45:1221-5.

  • Deutsche Krebshilfe 107406, Familial cancer and cancer etiology, 2007-2011 

  • BMBF 69120, Integrated genomic investigation of colorectal cancer, 2008-2011 

  • EU Health-FP7/2007-2013 260715 EU and North African migrants: health and health systems, 2011-2015